A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid TumorsScot Ebbinghaus, Lisa A. Hammond, Antti Jekunen et al.|Clinical Cancer Research|2005Cited by 49
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusionJeffrey G. Supko, Joseph P. Eder, Thomas J. Lynch et al.|Cancer Chemotherapy and Pharmacology|2000Cited by 30
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trialsD. Ross Camidge, Sanjay Popat, Yuichiro Ohe et al.|Lung Cancer|2025Cited by 3